Biomea Fusion Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.5%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$1.08next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 26-week topline data from Phase II Type 2 Diabetes trials (COVALENT-211 and COVALENT-212) | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Restricted Cash Quarterly45.1MTarget: Sufficient capital to fund operations into Q1 2027
Quarterly Net Loss Quarterly-12.4MTarget: Narrowing losses through disciplined R&D and G&A expense management
Icovamenib (BMF-219) Dosed Subjects Quarterly400.0Target: Expansion of Phase II cohorts and initiation of late-stage clinical trials
Watch Items
- Icovamenib (BMF-219) Phase II Type 2 Diabetes Trials (COVALENT-211 and COVALENT-212) Topline DataTrigger: 26-week HbA1c and glycemic control readoutsAction: Evaluate clinical efficacy, safety profile, and prepare for late-stage regulatory engagement
- BMF-650 Phase I GLP-131 Trial Initial Weight Loss DataTrigger: 28-day clinical weight reduction dataAction: Assess oral bioavailability, tolerability, and competitive positioning against existing GLP-1 therapies
- Cash Runway and Capital AllocationTrigger: Cash balance falling below 3 quarters of operating expensesAction: Explore strategic partnerships, regional licensing opportunities, or non-dilutive/dilutive financing options
Research as of 19 Jun 2026